Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
4(31%)
Results Posted
20%(1 trials)

Phase Distribution

Ph not_applicable
1
8%
Ph phase_2
2
15%
Ph phase_3
1
8%
Ph phase_4
5
38%

Phase Distribution

0

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
5(55.6%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

13

all time

Status Distribution
Active(6)
Completed(5)
Other(2)

Detailed Status

Completed5
Recruiting3
unknown2
Not yet recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (22.2%)
Phase 31 (11.1%)
Phase 45 (55.6%)
N/A1 (11.1%)

Trials by Status

unknown215%
completed538%
active_not_recruiting18%
not_yet_recruiting215%
recruiting323%

Recent Activity

4 active trials
Showing 5 of 13
completednot_applicable

SGLT2 Inhibitors in Treating Patients With PCOS

NCT05966792
recruitingphase_2

SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism

NCT07482020
recruiting

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

NCT06932081
active_not_recruiting

SGLT2-inhibitors on PC-AKI

NCT06491953
not_yet_recruitingphase_3

SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke

NCT07105917
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT05966792Not Applicable

SGLT2 Inhibitors in Treating Patients With PCOS

Completed
NCT07482020Phase 2

SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism

Recruiting
NCT06932081

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

Recruiting
NCT06491953

SGLT2-inhibitors on PC-AKI

Active Not Recruiting
NCT07105917Phase 3

SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke

Not Yet Recruiting
NCT05305911Phase 2

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Recruiting
NCT06449235Phase 4

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not Yet Recruiting
NCT05915884

The Triglyceride/Glucose Index and SGLT-2 Inhibitors

Completed
NCT04700839Phase 4

SGLT2 Inhibitors in Patients With PCOS

Completed
NCT02041234Phase 4

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

Completed
NCT02730377Phase 4

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Completed
NCT02284269

Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus

Unknown
NCT02528019Phase 4

Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

Unknown

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13